Table 3.
Published adrenal SBRT case series
| Study | Patients | Lesions | Primary Histology | Median Follow-up (mo) | Total Dose (Gy) | Pain Relief | Local Control | Overall Survival (median, mo) | Toxicity |
|---|---|---|---|---|---|---|---|---|---|
| Katoh et al, 200815 | 9 | 10 | 5 NSCLC 1 SCLC 2 HCC 1 prostate |
16 | 30-48 | yes, 1/1 patients | 100% | 15 | NR |
| Chawla et al, 20099 | 30 | 35 | 20 Lung 4 GI 3 breast 1 head and neck 1 melanoma 1 unknown |
9.8 | 16-50 | NR | 27% | 11 | Grade 1 nausea and fatigue “common” |
| Casamasssima et al, 20118 | 48 | 58 | 24 Lung 12 colon 4 melanoma 3 breast 1 uterus 1 unknown |
16.2 | 21.69-54.09 | yes, 4/4 patients | 94% | NR | 1 case grade 2 adrenal insufficiency |
| Torok et al, 201120 | 7 | 9 | 4 NSCLC 1 SCLC 2 HCC |
14 | 16 or 27 | yes, 1/2 patients | 89% | 8 | NR |
| Holy et al, 201114 | 13 | 13 | 13 NSCLC | 21 | 20-40 | yes, 6/8 patients | 77% | 23 | 46% grade 1 nausea, 15% gastric/duodenal ulcer |
| Oshiro et al, 201117 | 19 | 19 | 14 NSCLC 5 SCLC |
10.1 | 30-60 | NR | 72% | NR | 1 grade 2 duodenal ulcer |
| Guiou et al, 201213 | 9 | 10 | 4 NSCLC 5 SCLC |
7.3 (mean) | 40 | NR | NR | 10.2 | 22% nausea, vomiting |
| Scorsetti et al, 201219 | 34 | 36 | 22 NSCLC 3 SCLC 3 Melanoma 1 Sarcoma 1 Colorectal adenocarcinoma 1 RCC 1 Unknown |
41 | 20-37.5 | NR | 93% | 22 | 6% grade 2 nausea |
| Ahmed et al, 20137 | 13 | 13 | 4 NSCLC 2 RCC 1 melanoma 1 skin SCC 1 bladder 1 colon 1 cholangiocarcinoma |
12.3 | 33.75-60 | NR | 92% | 7.2 | 38% grade 1 fatigue 8% grade 1 abdominal pain 8% grade 1 diarrhea 15% grade 2 nausea 8% late grade 2 fatigue, abdominal pain, and nausea |
| Rudra et al, 201318 | 10 | 13 | 6 NSCLC 2 SCLC 2 RCC |
14.9 | 24-50 | NR | 73% | 17 | 80% grade 1-2 fatigue 40% grade 1-2 GI toxicity 1 case grade 2 adrenal insufficiency |
| Li et al, 201316 | 26 | 26 | 2 Pheochromocytoma 10 lung 6 bladder 4 unknown 4 RCC |
NR | 30-50 | yes, 15/16 patients | 77% | 17 | 88% grade 1-2 fatigue 69% grade 1-2 anorexia 38% grade 1-2 N/V 23% grade 1-2 skin rxn 4% grade 3 nausea/vomiting |
| Desai et al, 201510 | 14 | 14 | 6 NSCLC 2RCC 1 melanoma 1 primary adrenal 1 mixed Mullerian 1 GE junction 1 bladder 1 lymphoma |
NR | 20-30 | NR | 45.5% | NR | NR |
| Gamsiz et al, 201512 | 15 | 17 | 15 NSCLC | 16 | 30 | yes, 2/2 patients | 86.7% | NR | 46% grade 1 nausea 80% grade 1 fatigue 1 case dyspeptic disorder |
| Franzese et al 201611 | 46 | 46 | 30 lung 7 colorectal adenocarcinoma 9 other |
7.6 | 40 | NR | 78.3% | 28.5 (mean) | 13.1% pain, nausea, or vomiting 2 cases asthenia |
| Present study 2017 | 10 | 10 | 4 NSCLC 2 SCLC 1 esophageal carcinoma 1 HCC 1 leiomyosarcoma 1 unknown |
6 | 30-48 | yes, 4/4 patients | 70% | 9.9 | 36.4% nausea (grade 1 and 2) 27.3% fatigue (grade 1) 1 case diarrhea (grade 1) 1 case GI bleed |
GE, gastroesophageal; GI, gastrointestinal; HCC, hepatocellular carcinoma, NR, not reported; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer.